Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immatics NVIMTX +1.65%59 EV-to-EBITDA is -3.24 as of Jul. 27, 2026. GuruFocus rates IMTX with a GF Score™ of 59/100 and a GF Value™ of $3.38 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 404 Biotechnology companies, Immatics NV ranks worse than 247524.5% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Immatics NV's enterprise value is $762.66 Mil.
Immatics NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-235.13 Mil. Therefore, Immatics NV's EV-to-EBITDA for today is -3.24.
The historical rank and industry rank for Immatics NV's EV-to-EBITDA or its related term are showing as below:
IMTX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -27.74 Med: -3.5 Max: 22.48
Current: -3.24
During the past 8 years, the highest EV-to-EBITDA of Immatics NV was 22.48. The lowest was -27.74. And the median was -3.50.
IMTX's EV-to-EBITDA is ranked worse than 100% of 404
companies
in the Biotechnology industry
Industry Median: 11.82
vs IMTX: -3.24
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
Immatics NV (NAS:IMTX) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Immatics NV's PE Ratio (TTM) for today is calculated as:
Immatics NV's share price for today is $9.23.
Immatics NV's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.999.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Immatics NV's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immatics NV's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immatics NV EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immatics NV's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Immatics NV's EV-to-EBITDA falls into.
Immatics NV's current Enterprise Value is $762.66 Mil.
Immatics NV's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-235.13 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immatics NV (IMTX) has a EV-to-EBITDA of -3.24 as of Jul. 27, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Immatics NV. According to the industry distribution chart, Immatics NV ranks #999999 out of 404 companies in the Biotechnology industry.
Is Immatics NV's EV-to-EBITDA too high?
Immatics NV's current EV-to-EBITDA is -3.24. Based on the distribution chart, Immatics NV ranks #999999 out of 404 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Immatics NV has a GF Score™ of 59/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Immatics NV's EV-to-EBITDA compare to TRAX and AVLN?
According to the Biotechnology industry distribution chart, Immatics NV ranks #999999 out of 404 companies for EV-to-EBITDA. This places Immatics NV in the lower half of its industry. The industry median EV-to-EBITDA is 11.82. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 11.82, based on 404 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Immatics NV. For the Biotechnology industry, the median EV-to-EBITDA is 11.82 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immatics NV's current EV-to-EBITDA is -3.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immatics NV stock overvalued right now?
Based on GuruFocus' analysis, Immatics NV (IMTX) is currently considered Significantly Overvalued. The stock's GF Value™ is $3.38, compared to a current price of $9.23 — trading 173.1% above its estimated fair value. The current EV-to-EBITDA is -3.24. Immatics NV's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Immatics NV (IMTX), the current EV-to-EBITDA is -3.24 as of Jul. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immatics NV (IMTX) Overvalued in 2026?
Based on GuruFocus' analysis, Immatics NV stock appears to be overvalued.
The current stock price of $9.23 is trading 173.1% above its estimated GF Value™ of $3.38.
GuruFocus considers Immatics NV to be Significantly Overvalued.
Key valuation signals for IMTX:
EV-to-EBITDA: -3.24
GF Value™: $3.38 vs. price of $9.23 (173.1% above fair value)
No single metric tells the full story. See the IMTX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
59GF Score
Get the complete analysis for IMTX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMTX has been successfully added to your 
